Leydig cell tumor - benign
Also known as: Fibroid, Leiomyoma, Fibrous, Tumor
Methodology & AI Transparency ⓘ
Leydig cell tumor - benign Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Cancer, Oncology & Supportive Care diagnostic criteria (D27.9), workup for Leydig cell tumor - benign (also termed Fibroid or Leiomyoma) integrates immunohistochemistry [Leydig cell tumor - benign D27.9] with evidence-graded therapy tailored to Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging) response.
- 2 Real-world patient consensus: Synonyms for Leydig cell tumor - benign (D27.9): Fibroid, Leiomyoma, Fibrous (Cancer & Oncology).
- 3 Typical cash cost range: Primary evaluation for Leydig cell tumor - benign incorporates immunohistochemistry [Leydig cell tumor - benign D27.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Leydig cell tumor - benign monitoring tracks Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging) toward Guideline-concordant surveillance (D27.9).
Ask our AI Specialists anything about Leydig cell tumor - benign
What Is Leydig cell tumor - benign?
Under Cancer, Oncology & Supportive Care diagnostic criteria (D27.9), workup for Leydig cell tumor - benign (also termed Fibroid or Leiomyoma) integrates immunohistochemistry [Leydig cell tumor - benign D27.9] with evidence-graded therapy tailored to Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Leydig cell tumor - benign (D27.9) center on angiogenesis [Leydig cell tumor - benign D27.9]. targeted cancer & oncology interventions aim to normalize Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • Presentation of Leydig cell tumor - benign (D27.9): abnormality detected early in Leydig cell tumor - benign (D27.9: on age-appropriate screening)
- • Secondary Leydig cell tumor - benign clinical sign: persistent painless lump, in Leydig cell tumor - benign (D27.9: non-healing ulcer/mole change,)
- • Symptom flares in Leydig cell tumor - benign correlating with Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging) deviation outside Guideline-concordant surveillance (D27.9)
- • Functional cancer & oncology impact requiring immunohistochemistry [Leydig cell tumor - benign D27.9] evaluation (D27.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Leydig cell tumor - benign Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D27.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Leydig cell tumor - benign (D27.9: Genomic Staging) | Guideline-concordant surveillance (D27.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Leydig cell tumor - benign (D27.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D27.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Leydig cell tumor - benign (D27.9: Organ Function Panel) | Preserved renal/hepatic clearance (D27.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Leydig cell tumor - benign
Treatment selection for Leydig cell tumor - benign depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leydig cell tumor - benign)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Deutenzalutamide, a novel androgen receptor inhibitor, after progression on In summary, deutenzalutamide significantly prolonged rPFS and, after adjustment, showed a potential OS benefit with a favorable safety profile, supporting its promise as a new treatment option for mCRPC. Signal transduction and targeted therapy • 2026-04-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41968137 ↗ |
| New Insights on Cost-effectiveness of prophylactic cranial irradiation in stage III non-small: What a 670-Participant Study Found PCI is cost-effective compared to no PCI in stage III NSCLC, and could therefore, from a cost-effectiveness perspective, be considered in routine care. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2022-05-15 • Phase III Randomized Trial | N = 670 | 87/100 | PMID 35259416 ↗ |
| Can This Approach Help? Inside the Latest Research on Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in LY75 and GPR160 participate in epithelial-to-mesenchymal transition and growth pathways, in both cases with SNP-dependent variation in regulation. Clinical pharmacology and therapeutics • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34048027 ↗ |
| Can This Approach Help? Inside the Latest Research on A genetically defined signature of responsiveness to erlotinib in early-stage This study identified five biologically distinct patient clusters with different actionable lesions and unravelled a previously unappreciated association of SMAD4 alteration status with erlotinib effectiveness. EBioMedicine • 2021-04-15 • Phase III Randomized Trial | N = 91 | 82/100 | PMID 33862582 ↗ |
| Can This Approach Help? Inside the Latest Research on Alpelisib for the treatment of PIK3CA -mutated, hormone receptor-positive, The PFS benefit appears clinically significant over fulvestrant alone, with a 7.9 months, non-significant, improvement in overall survival. Expert opinion on pharmacotherapy • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33622114 ↗ |
Leydig cell tumor - benign Patient Community & “People Like Me” Threads
Filter Leydig cell tumor - benign community threads and patient logs by age, biological sex, dosage, and treatment duration.